<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116948</url>
  </required_header>
  <id_info>
    <org_study_id>20030289</org_study_id>
    <nct_id>NCT00116948</nct_id>
  </id_info>
  <brief_title>A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter</brief_title>
  <official_title>A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomet Merck Aps,Horsens, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gigtforeningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahva A/S, Borgervænget 5-7, København Ø, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danske Fysioterapeuter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regionshospitalet Silkeborg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Institute of Occupational Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regionshospitalet Hammel Neurocenter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two total hip replacement systems: Hip Resurfacing&#xD;
      System (ReCap) versus Mallory-Head/Exeter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Denmark approximately 7000 primary hip replacements are implanted yearly, and the&#xD;
      incidence is rising with the increasingly aging population. For older patients, the incidence&#xD;
      of later revisions of hip implantation is low. Unfortunately, this is not true for younger&#xD;
      patients. Approximately 20% of patients under 55 years of age at the time of surgery must&#xD;
      have the hip implant renewed within 10 years.&#xD;
&#xD;
      This is primarily because of the wear generated by polyethylene debris. The polyethylene is&#xD;
      associated with osteolysis in the proximity of the prosthesis leading to failure of the&#xD;
      prosthesis.&#xD;
&#xD;
      This unsatisfactory result has led to the development of an alternative hip prosthesis&#xD;
      especially to benefit younger and physically active people. The new prosthesis should produce&#xD;
      less inflammatory debris and less osteolysis induced failure.&#xD;
&#xD;
      To avoid the polyethylene particles, a new type of prosthesis has been made articulating&#xD;
      metal on metal. The Hip Resurfacing System consists of an alloy of chrome - cobalt -&#xD;
      molybdenum. Another point of interest for this prosthesis is also the size of the&#xD;
      articulating surfaces which are bigger than usual. This will theoretically participate in the&#xD;
      generation of metal ions.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
        -  This randomised prospective study will investigate the emission of Co-, Cr- and Mb-ions&#xD;
           from Hip Resurfacing System and Mallory-Head/Exeter implants, respectively. The emission&#xD;
           is measured as the ion concentration in the urine and is correlated to the inflammatory&#xD;
           response in fasting plasma before and after the operation.&#xD;
&#xD;
        -  To assess the walking pattern postoperatively using a 3D gait analysis, Vicon Polygon.&#xD;
&#xD;
        -  To assess the postoperative recovery using the Harris hip score and visual analogue&#xD;
           scale.&#xD;
&#xD;
        -  The migration of acetabular components will be evaluated by RSA, performing&#xD;
           radiostereometric analyses at the Orthopaedic Center, Aarhus University Hospital. The&#xD;
           follow-up RSA will be scheduled for week 1, as well as 3 months, 12 months, 24 months,&#xD;
           and 5 years after surgery. Bone mineral density around the implanted femoral component&#xD;
           will be examined by DEXA scan at week 1, as well as 1 year and 2 years after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metal ion release evaluated in urine</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait pattern evaluated with 3D gait analysis, Vicon Polygon</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone mineral density (BMD) in surrounding bone of the prosthesis</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostheses migration evaluated by radiostereometric analysis (RSA)</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proinflammatory- and bone degradation measures in blood samples</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteoarthrosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReCap, Hip resurfacing system, Biomet</intervention_name>
    <description>ReCap total hip arthroplasty inserted according to manufactures manual.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with primary hip osteoarthrosis (OA).&#xD;
&#xD;
          -  Informed patient consent in writing.&#xD;
&#xD;
          -  Sufficient bone density to allow uncemented implantation of an acetabular component.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of other metal implants.&#xD;
&#xD;
          -  Working exposure of chrome, cobalt or molybdenum.&#xD;
&#xD;
          -  Ingestion of multivitamin or medication containing chrome, cobalt or molybdenum.&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Hip joint dysplasia&#xD;
&#xD;
          -  Patients with neuromuscular or vascular disease in the affected leg.&#xD;
&#xD;
          -  Patients who regularly take non-steroid anti-inflammatory drugs (NSAID) and cannot&#xD;
             interrupt intake for the postoperative phase of the study.&#xD;
&#xD;
          -  Patients with fracture sequelae.&#xD;
&#xD;
          -  Female patients of childbearing capacity.&#xD;
&#xD;
          -  Sequelae to previous hip joint disorder in childhood&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjeld Søballe, MD., Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic Center, Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopaedic Center, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Jylland</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2005</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthrosis</keyword>
  <keyword>RSA</keyword>
  <keyword>DEXA</keyword>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Metal ion</keyword>
  <keyword>Inflammatory response</keyword>
  <keyword>Gait analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

